NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中樞神經系統障礙治療藥市場:各疾病類型、藥物類型、流通管道、地區-規模,佔有率,展望,機會分析(2021年∼2028年)

Central Nervous System Disorders Therapeutics Market, by Disease Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

出版商 Coherent Market Insights 商品編碼 1021674
出版日期 內容資訊 英文 170 Pages
商品交期: 2-3個工作天內
價格
中樞神經系統障礙治療藥市場:各疾病類型、藥物類型、流通管道、地區-規模,佔有率,展望,機會分析(2021年∼2028年) Central Nervous System Disorders Therapeutics Market, by Disease Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
出版日期: 2021年07月27日內容資訊: 英文 170 Pages
簡介

中樞神經系統障礙,原因是外傷、感染疾病、腫瘤、血流障礙、自體免疫疾病等造成。中樞神經系統障礙治療藥市場企業,由於開發中樞神經系統障礙的更有效率的治療方法進行臨床試驗,預計在預測期間推動市場成長。還有市場參與企業著重產品的銷售,預期強化該市場的地位。

本報告提供全球中樞神經系統障礙治療藥市場的相關調查,市場規模和預測,成長及阻礙因素,機會,COVID-19的影響,各疾病類型、藥物類型、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各疾病類型
    • 市場明細:各藥物類型
    • 市場明細:各流通管道
    • 市場明細:各地區
  • Coherent Opportunity Map (COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • PEST分析
  • 產業趨勢
  • 開發平台分析
  • 主要的焦點
  • 流行病學
  • 價格分析
  • 法規方案
  • 全球供應鏈分析

第4章 COVID-19影響分析

  • COVID-19流行病學
  • COVID-19對中樞神經系統障礙治療藥的需求與供給的影響
  • COVID-19對中樞神經系統障礙治療藥市場的影響

第5章 全球中樞神經系統障礙治療藥市場:各疾病類型(2017-2028)

  • 簡介
  • 神經血管疾病
  • 創傷
  • 心理健康
  • 焦慮症
  • 癲癇
  • 其他
  • 退化性疾病
  • 阿茲海默症
  • 帕金森氏症
  • 多發性硬化症
  • 其他
  • 感染疾病
  • 中樞神經系統癌症
  • 其他

第6章 全球中樞神經系統障礙治療藥市場:各藥物類型(2017-2028)

  • 簡介
  • 止痛藥
  • 麻醉劑
  • 抗帕金森藥
  • 抗癲癇
  • 其他

第7章 全球中樞神經系統障礙治療藥市場:各流通管道(2017-2028)

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 其他

第8章 全球中樞神經系統障礙治療藥市場:各地區(2017-2028)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章 競爭情形

  • 企業簡介
    • Pfizer Inc.
    • Biogen
    • Otsuka Pharmaceutical Co. Ltd.
    • Merck &Co.
    • AstraZeneca
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • Johnson &Johnson Private Limited
    • Eli Lilly and Company
    • Sanofi
    • GlaxoSmithKline plc.
    • Boehringer Ingelheim International GmbH
  • 分析師的見解

第10章 Section

目錄

The nervous system comprises of peripheral nervous system (PNS) and central nervous system (CNS). The CNS consists of spinal cord and brain and the PNS consists of all the neural elements other than the brain and spinal cord i.e. cranial nerves, peripheral nerves, spinal nerves, and neuromuscular junctions. CNS disorders may be caused due to trauma, infections, tumors, blood flow disruption, autoimmune disorders, and others. Trauma such as traumatic brain injury or intracranial injury is a result of external trauma such as vehicle collision, violence, and others. The severity of traumatic brain injury can range from mild to severe depending upon the impact of the traumatic force injuring the head. CNS infection may be caused due to bacteria, protozoa, virus, fungus, and prions. Meningitis, encephalitis, amoebic brain abscess, poliomyelitis, kuru, rabies, malaria, and toxoplasmosis are some of the common CNS infections. Autoimmune disorders such as Parkinson disease and multiple sclerosis affect the nervous system by damaging the neural cells.

Market Dynamics

Market players are conducting clinical trials for developing more efficient treatments for CNS disorders, which could contribute to the growth of the global central nervous system disorders therapeutics market over the forecast period. For instance, in 2017, Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical company and Ovid Therapeutics Inc., a U.S. based biopharmaceutical company initiated a collaborative clinical trial study to investigate the potential safety and tolerability of novel TAK-935 drug which was co-developed by both the companies. TAK-935 is used to treat epileptic encephalopathy, a group of disorders which cause malfunctioning of cerebral part of the brain. The results of this study show that TAK-935 drug was well tolerated within the test population and also a decreased frequency of seizures was observed during the study period.

Market players are focusing on launch of products, which is expected to strengthen their position in the global central nervous system disorders therapeutics market. For instance, in February 2018, Sandoz International GmbH, a subsidiary of Novartis AG, a Swiss pharmaceutical company received the U.S. Food and Drug Administration (FDA) approval for its product Glatopa (40 mg/mL). Glatopa is the generic form of Copaxone which is developed by Teva Pharmaceutical Industries Ltd., an Israeli pharmaceutical company for the treatment of multiple sclerosis. Sandoz International GmbH has taken an initiative known as Sandoz GlatopaCare to offer free of cost support program to help patients suffering from multiple sclerosis in administering Glatopa injection.

Key features of the study:

  • This report provides an in-depth analysis of global central nervous system disorders therapeutics market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global central nervous system disorders therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Pfizer Inc., Biogen, Otsuka Pharmaceutical Co. Ltd., Merck & Co., AstraZeneca, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Johnson & Johnson Private Limited, Eli Lilly and Company, Sanofi, GlaxoSmithKline plc., and Boehringer Ingelheim International GmbH
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global central nervous system disorders therapeutics market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global central nervous system disorders therapeutics market

Detailed Segmentation:

  • Global Central Nervous System Disorders Therapeutics Market, By Disease Type:
    • Neurovascular Diseases
    • Central Nervous System Trauma
    • Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Others
    • Degenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others
    • Infectious Diseases
    • Central Nervous System Cancer
    • Others
  • Global Central Nervous System Disorders Therapeutics Market, By Drug Type:
    • Analgesics
    • Anesthetics
    • Anti-Parkinson Drugs
    • Anti-Epileptics
    • Others
  • Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • Global Central Nervous System Disorders Therapeutics Market, By Region:
    • North America
  • By Disease Type:
    • Neurovascular Diseases
    • Trauma
    • Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Others
    • Degenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others
    • Infectious Diseases
    • Central Nervous System Cancer
    • Others
  • By Drug Type:
    • Analgesics
    • Anesthetics
    • Anti-Parkinson Drugs
    • Anti-Epileptics
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • By Country:
    • U.S.
    • Canada
    • Latin America
  • By Disease Type:
    • Neurovascular Diseases
    • Trauma
    • Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Others
    • Degenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others
    • Infectious Diseases
    • Central Nervous System Cancer
    • Others
  • By Drug Type:
    • Analgesics
    • Anesthetics
    • Anti-Parkinson Drugs
    • Anti-Epileptics
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
  • By Disease Type:
    • Neurovascular Diseases
    • Trauma
    • Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Others
    • Degenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others
    • Infectious Diseases
    • Central Nervous System Cancer
    • Others
  • By Drug Type:
    • Analgesics
    • Anesthetics
    • Anti-Parkinson Drugs
    • Anti-Epileptics
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Disease Type:
    • Neurovascular Diseases
    • Trauma
    • Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Others
    • Degenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others
    • Infectious Diseases
    • Central Nervous System Cancer
    • Others
  • By Drug Type:
    • Analgesics
    • Anesthetics
    • Anti-Parkinson Drugs
    • Anti-Epileptics
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
  • By Disease Type:
    • Neurovascular Diseases
    • Trauma
    • Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Others
    • Degenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others
    • Infectious Diseases
    • Central Nervous System Cancer
    • Others
  • By Drug Type:
    • Analgesics
    • Anesthetics
    • Anti-Parkinson Drugs
    • Anti-Epileptics
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Disease Type:
    • Neurovascular Diseases
    • Trauma
    • Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Others
    • Degenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others
    • Infectious Diseases
    • Central Nervous System Cancer
    • Others
  • By Drug Type:
    • Analgesics
    • Anesthetics
    • Anti-Parkinson Drugs
    • Anti-Epileptics
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
  • Pfizer Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Biogen
  • Otsuka Pharmaceutical Co. Ltd.
  • Merck & Co.
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • Sanofi
  • GlaxoSmithKline plc.
  • Boehringer Ingelheim International GmbH

* marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Disease Type
    • Market Snippet, By Drug Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • PEST Analysis
  • Industry Trends
  • Pipeline Analysis
  • Key Highlights
  • Epidemiology
  • Pricing Analysis
  • Regulatory Scenario
  • Global Supply Chain Analysis

4. COVID - 19 Impact Analysis

  • COVID-19 Epidemiology
  • Impact of COVID-19 on Demand and Supply of Central Nervous System Disorders Therapeutics
  • Impact of Covid-19 on the Central Nervous System Disorders Therapeutics Market

5. Global Central Nervous System Disorders Therapeutics Market, By Disease Type, 2017-2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Neurovascular Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Trauma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Mental Health
  • Anxiety Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Epilepsy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Degenerative Diseases
  • Alzheimer's Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Parkinson's Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Multiple Sclerosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Infectious Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Central Nervous System Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Central Nervous System Disorders Therapeutics Market, By Drug Type, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Analgesics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Anesthetics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Anti-Parkinson Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Anti-Epileptics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Central Nervous System Disorders Therapeutics Market, By Region, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Company Profiles
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Biogen
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Otsuka Pharmaceutical Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Merck & Co.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • AstraZeneca
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Johnson & Johnson Private Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Sanofi
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Boehringer Ingelheim International GmbH
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact